Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

Article  PubMed  Google Scholar 

Elgaml A, Elegezy M, El-Mesery M, El-Mowafy M. Natural variability in surface antigen and reverse transcriptase domain of hepatitis B virus in treatment-naïve chronic HBV-infected Egyptian patients. Virus Res. 2021;302:198422.

Article  CAS  PubMed  Google Scholar 

El-Mesery M, El-Mowafy M, Elgaml A, Youssef LF, Abed SY. Correlation of Serum soluble fibrinogen-like protein 2 with soluble FAS Ligand and interferon gamma in egyptian hepatitis C virus-infected patients and hepatocellular carcinoma patients. J Interferon Cytokine Res. 2017;37:342–7.

Article  CAS  PubMed  Google Scholar 

El-Mesery M, El-Mowafy M, Youssef LF, El-Mesery A, Abed SY, Elgaml A. Serum soluble fibrinogen-like protein 2 represents a novel biomarker for differentiation between acute and chronic egyptian hepatitis b virus-infected patients. J Interferon Cytokine Res. 2021;41:52–9.

Article  CAS  PubMed  Google Scholar 

El-Mowafy M, Elegezy M, El-Mesery M, Elgaml A. Novel method for cloning of hepatitis B virus DNA using the In-Fusion enzyme. Gene Rep. 2023;31:101765.

Article  CAS  Google Scholar 

El-Mowafy M, Elgaml A, El-Mesery M, Elegezy M. Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura. J Med Virol. 2017;89:1559–66.

Article  CAS  PubMed  Google Scholar 

Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287.

Article  PubMed  PubMed Central  Google Scholar 

Kimura O, Kondo Y, Kogure T, Kakazu E, Ninomiya M, Iwata T, Morosawa T, Shimosegawa T. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int. 2014;2014:172913.

Article  PubMed  PubMed Central  Google Scholar 

Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res. 2007;67:10831–9.

Article  CAS  PubMed  Google Scholar 

Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3326–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamanaka C, Wada H, Eguchi H, Hatano H, Gotoh K, Noda T, Yamada D, Asaoka T, Kawamoto K, Nagano H, et al. Clinical significance of CD13 and epithelial mesenchymal transition (EMT) markers in hepatocellular carcinoma. Jpn J Clin Oncol. 2018;48:52–60.

Article  PubMed  Google Scholar 

Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res. 2014;34:1709–13.

CAS  PubMed  PubMed Central  Google Scholar 

Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22:823–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, Tang S, Liu H, Zhang F, Huang J, et al. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3:11–40.

Article  PubMed  PubMed Central  Google Scholar 

Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol. 2010;176:472–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao SB, Zheng QF, Xu B, Pan CB, Li KL, Zhao Y, Zheng QL, Lin X, Xue LX, Jin GH. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma. Mol Cancer Res. 2014;12:1388–97.

Article  CAS  PubMed  Google Scholar 

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, Chan WP, Chou RH. EZH2 in cancer progression and potential application in cancer therapy: A friend or foe? Int J Mol Sci. 2017;18:1172.

Article  PubMed  PubMed Central  Google Scholar 

Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci USA. 2016;113:E3735–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015;6:6051.

Article  CAS  PubMed  Google Scholar 

Zhao L, Yu Y, Wu J, Bai J, Zhao Y, Li C, Sun W, Wang X. Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene. 2014;537:197–202.

CAS  Google Scholar 

Collinson A, Collier AJ, Morgan NP, Sienerth AR, Chandra T, Andrews S, Rugg-Gunn PJ. Deletion of the polycomb-group protein EZH2 leads to compromised self-renewal and differentiation defects in human embryonic stem cells. Cell Rep. 2016;17:2700–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res. 2018;6:34.

Article  PubMed  PubMed Central  Google Scholar 

Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frankel AE, Liu X, Minna JD. Developing EZH2-targeted therapy for lung cancer. Cancer Discov. 2016;6:949–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics. 2016;8:57.

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Kim S, Ryu WS. DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids. J Virol. 2009;83:5815–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pasini D, Di Croce L. Emerging roles for Polycomb proteins in cancer. Curr Opin Genet Dev. 2016;36:50–8.

Article  CAS  PubMed  Google Scholar 

Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017;29:375–81.

Article  CAS  PubMed  Google Scholar 

Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget. 2017;8:37974–90.

Article  PubMed  PubMed Central  Google Scholar 

Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110:7922–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song X, Zhang L, Gao T, Ye T, Zhu Y, Lei Q, Feng Q, He B, Deng H, Yu L. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation. Biomed Pharmacother. 2016;81:288–94.

Article  CAS  PubMed  Google Scholar 

Italiano A. Targeting epigenetics in sarcomas through EZH2 inhibition. J Hematol Oncol. 2020;13:33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dollé L, Theise ND, Schmelzer E, Boulter L, Gires O, van Grunsven LA. EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol. 2015;308:G233–50.

Article  PubMed  Google Scholar 

Li Y, Farmer RW, Yang Y, Martin RC. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. BMC Cancer. 2016;16:228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hachmeister M, Bobowski KD, Hogl S, Dislich B, Fukumori A, Eggert C, Mack B, Kremling H, Sarrach S, Coscia F, et al. Regulated intramembrane proteolysis and degradation of murine epithelial cell adhesion molecule mEpCAM. PLoS ONE. 2013;8:e71836.